Vanda Pharmaceuticals Inc
NASDAQ:VNDA 4:00:00 PM EDT
| Market Cap (Intraday) | 372.49M |
| Current PE | 59.36 |
| Forward PE | 17.73 |
| 2yr Forward PE | 27.33 |
| 10-Day MA | $6.50 |
| 50-Day MA | $7.01 |
| 200-Day MA | $9.29 |
Vanda Pharmaceuticals Inc Stock, NASDAQ:VNDA
2200 Pennsylvania Avenue NW, Suite 300E, Washington, District of Columbia 20037
United States of America
Phone: +1.202.734.3400
Number of Employees: 290
Description
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.